Double or Triple?, page-24

Be aware that it is a net number. Having seen other such trailing commissions structures for drugs the internal ongoing costs the company puts on th edrug are astonishing ( marketing , junkets the full works and % of corporate costs etc etc) and until those ongoing costs Nadda comes home and then all the development costs are paid backso nothing flows for quite a period IMO. We will never see the fine print. .
Generic competition at much lower price changes market bit other side is a better drug regimine in patent will command a high price if it has signifiicant inprovement in dosage , effectiveness or side affects . Uptake and insurance companies can be slow as well or fast if it is ecconomically better.